Tibet Weixinkang Medicine Co Ltd (603676) — Cash Flow-to-Debt Ratio
Tibet Weixinkang Medicine Co Ltd (603676) has a Cash Flow-to-Debt Ratio of 0.04x as of September 2025, meaning its operating cash flow of CN¥13.68 Million could theoretically repay 0% of its total liabilities (CN¥382.95 Million) in one year. See Tibet Weixinkang Medicine Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tibet Weixinkang Medicine Co Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Tibet Weixinkang Medicine Co Ltd across 12 annual periods. Also explore Tibet Weixinkang Medicine Co Ltd (603676) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Tibet Weixinkang Medicine Co Ltd (2013–2024)
Year-by-year debt coverage analysis for Tibet Weixinkang Medicine Co Ltd. For market capitalisation and broader financial context, see market value of Tibet Weixinkang Medicine Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.80x | CN¥372.78 Million | CN¥468.24 Million | ▲ +35.4% |
| 2023 | 0.59x | CN¥256.67 Million | CN¥436.55 Million | ▲ +6.1% |
| 2022 | 0.55x | CN¥246.15 Million | CN¥444.13 Million | ▲ +39.1% |
| 2021 | 0.40x | CN¥170.69 Million | CN¥428.31 Million | ▲ +12.3% |
| 2020 | 0.35x | CN¥133.70 Million | CN¥376.85 Million | ▲ +25.0% |
| 2019 | 0.28x | CN¥106.34 Million | CN¥374.56 Million | ▲ +15.2% |
| 2018 | 0.25x | CN¥83.17 Million | CN¥337.33 Million | ▼ -38.2% |
| 2017 | 0.40x | CN¥63.30 Million | CN¥158.58 Million | ▼ -64.3% |
| 2016 | 1.12x | CN¥103.79 Million | CN¥92.94 Million | ▲ +3.2% |
| 2015 | 1.08x | CN¥114.47 Million | CN¥105.82 Million | ▼ -29.6% |
| 2014 | 1.54x | CN¥118.47 Million | CN¥77.09 Million | ▲ +6.7% |
| 2013 | 1.44x | CN¥88.59 Million | CN¥61.52 Million | — |